

Michel van Gelder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1772130/publications.pdf>

Version: 2024-02-01

38
papers

806
citations

933447

10
h-index

501196

28
g-index

39
all docs

39
docs citations

39
times ranked

1683
citing authors

#	ARTICLE	IF	CITATIONS
1	Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. <i>Blood Advances</i> , 2022, 6, 3378-3385.	5.2	45
2	Controlling a human parainfluenza virus-3 outbreak in a haematology ward in a tertiary hospital: the importance of screening strategy and molecular diagnostics in relation to clinical symptoms. <i>Journal of Hospital Infection</i> , 2022, 126, 56-63.	2.9	4
3	Real-world experience: Introduction of T cell replete haploidentical transplantations in a single center. <i>EJHaem</i> , 2021, 2, 440-448.	1.0	1
4	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
5	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
6	Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 4430-4437.	5.2	23
7	Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 584520.	4.8	11
8	Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 147-154.	3.5	10
9	Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. <i>Blood</i> , 2019, 134, 1-1.	1.4	47
10	Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2019, 134, 2053-2053.	1.4	0
11	Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial. <i>Blood</i> , 2019, 134, 371-371.	1.4	0
12	Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 52-57.	0.4	7
13	Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. <i>Cancer Epidemiology</i> , 2018, 57, 90-96.	1.9	10
14	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	1.4	19
15	Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. <i>Oncotarget</i> , 2018, 9, 20590-20604.	1.8	16
16	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
17	Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 421-433.	2.5	1
18	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 667-675.e2.	0.4	12

#	ARTICLE	IF	CITATIONS
19	Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. <i>Haematologica</i> , 2017, 102, 1629-1639.	3.5	111
20	Permitting patients to pay for participation in clinical trials: the advent of the P4 trial. <i>Medicine, Health Care and Philosophy</i> , 2017, 20, 219-227.	1.8	6
21	Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT). <i>Blood</i> , 2016, 128, 832-832.	1.4	10
22	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3504-3504.	1.4	0
23	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. <i>Journal of Hematology and Oncology</i> , 2015, 8, 4.	17.0	37
24	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Soci�t� Fran�saise de Greffe de Moelle et Therapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1515-1523.	2.0	11
25	Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 951-963.	4.2	47
26	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. <i>Blood</i> , 2015, 126, 3209-3209.	1.4	1
27	Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 2561-2561.	1.4	3
28	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society. <i>Blood</i> , 2014, 124, 542-542.	1.4	0
29	R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 2883-2883.	1.4	0
30	First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. <i>Blood</i> , 2012, 120, 57-57.	1.4	5
31	Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 773-781.	2.5	11
32	Resolution of Waldenstr�m's macroglobulinemia related isolated neutropenia by immunochemotherapy. <i>American Journal of Hematology</i> , 2011, 86, 380-382.	4.1	2
33	First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,. <i>Blood</i> , 2011, 118, 4110-4110.	1.4	3
34	R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial,. <i>Blood</i> , 2011, 118, 3911-3911.	1.4	6
35	Complex Karyotype Predicts Outcome Better Than Monosomal Karyotype In Patients with MDS/Secondary Acute Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): a Retrospective Survey on Behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 578-578.	1.4	2
36	Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial). <i>Blood</i> , 2010, 116, 2395-2395.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Effective Alloreactive NK Cell Therapy for Breast Cancer In Mice Requires Conditioning with Cyclophosphamide and Total Body Irradiation but Not Bone Marrow Engraftment. Blood, 2010, 116, 2085-2085.	1.4	0
38	Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.. Blood, 2006, 108, 2400-2400.	1.4	1